Chapter 4 · Management

They won big once. Now they're reinvesting it all.

The team that scaled the COVID vaccine is plowing the proceeds into the next generation of mRNA bets.

↓ scroll to read

✦ The bottom line

Moderna's long-tenured, founder-led leadership made the aggressive bet to scale an mRNA COVID vaccine — and it paid off enormously. The same team is now making the defining capital-allocation call of the post-boom era: how much of the war chest to spend, and on which pipeline programs, while the core business shrinks.

↓ the brief below

✦ Teach me

Conviction vs. discipline

Moderna's management has deep conviction in the mRNA platform — that conviction built a vaccine at record speed. But conviction cuts both ways: spending billions a year on a broad pipeline is a bet that several programs will pay off. If they're right, the platform compounds; if they over-spend on misses, the war chest erodes for little return. The judgment to watch: are they focusing the spend on the highest-probability programs (like the Merck cancer vaccine), or spreading it too thin?

With a shrinking core and a big cash pile, management's spending discipline *is* the investment thesis. You're betting on their judgment about which mRNA bets deserve the winnings.

High conviction